Loading patent…
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsPatrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
Estimating the term…
The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
A method of treating a trauma induced demyelinating peripheral neuropathy, the method comprising administering a therapeutically effective amount of polyclonal IgG to a mammal diagnosed with said neuropathy, wherein the polyclonal IgG is administered systemically or locally to the site of the trauma.
Dependencies are inferred from the claim text.